Matches in Wikidata for { <http://www.wikidata.org/entity/Q93207435> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- Q93207435 description "article scientifique publié en 2020" @default.
- Q93207435 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q93207435 description "scientific article published on 01 April 2020" @default.
- Q93207435 description "wetenschappelijk artikel" @default.
- Q93207435 description "наукова стаття, опублікована 1 квітня 2020" @default.
- Q93207435 name "A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)" @default.
- Q93207435 name "A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)" @default.
- Q93207435 type Item @default.
- Q93207435 label "A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)" @default.
- Q93207435 label "A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)" @default.
- Q93207435 prefLabel "A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)" @default.
- Q93207435 prefLabel "A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)" @default.
- Q93207435 P1476 Q93207435-9142BAB5-3BC9-4FD2-8F79-93C589B0C745 @default.
- Q93207435 P2093 Q93207435-173D29F6-F609-4B36-B41B-BB42A6FAF6B1 @default.
- Q93207435 P2093 Q93207435-1A27A8D0-5558-44BA-9B5E-C559BD84FB3D @default.
- Q93207435 P2093 Q93207435-42581C05-5090-45ED-A8E6-F853627B0147 @default.
- Q93207435 P2093 Q93207435-522C8AA0-AACC-47B3-B697-DBF008C83B65 @default.
- Q93207435 P2093 Q93207435-56880ADC-236F-48DE-A081-474FA32DA7F2 @default.
- Q93207435 P2093 Q93207435-C81D3031-2EC9-41F7-B8A2-7422E17527BE @default.
- Q93207435 P2093 Q93207435-D285E3FB-1A42-49E2-8D78-5E916651BDFB @default.
- Q93207435 P2093 Q93207435-F048CDA4-EE62-4C16-A42A-1050FBB36B21 @default.
- Q93207435 P304 Q93207435-05A0C99D-80D3-4042-AC60-3E459DFD5387 @default.
- Q93207435 P31 Q93207435-E92677E5-58B8-48D1-98E4-F47A02A910A6 @default.
- Q93207435 P356 Q93207435-A6823DBD-3893-4FBD-8AF1-7EC6BF49D769 @default.
- Q93207435 P433 Q93207435-A8B909C6-6757-4DED-AEDC-DECB67D6C3C2 @default.
- Q93207435 P478 Q93207435-B794BA18-F3E3-4E31-BC63-FBF5DC1A7D5B @default.
- Q93207435 P50 Q93207435-51E0F1F1-4796-4B4C-898E-A93BEE8B6984 @default.
- Q93207435 P50 Q93207435-D4879F12-157C-49B3-BF14-E09B85CC3B80 @default.
- Q93207435 P577 Q93207435-4EFD71FE-BAA4-44AB-9CE3-7FBF9A9A6394 @default.
- Q93207435 P698 Q93207435-C1E1D39C-D80C-4FCC-A3C9-6845ADBE3BCD @default.
- Q93207435 P932 Q93207435-5A9467C7-5807-477E-8814-F32CC19B5CCB @default.
- Q93207435 P356 BLOODADVANCES.2019001278 @default.
- Q93207435 P698 32330241 @default.
- Q93207435 P1476 "A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)" @default.
- Q93207435 P2093 "Anna B Moseley" @default.
- Q93207435 P2093 "Daniel J DeAngelo" @default.
- Q93207435 P2093 "Harry P Erba" @default.
- Q93207435 P2093 "Jeffrey E Lancet" @default.
- Q93207435 P2093 "Martin S Tallman" @default.
- Q93207435 P2093 "Megan Othus" @default.
- Q93207435 P2093 "Rami S Komrokji" @default.
- Q93207435 P2093 "Steven E Coutre" @default.
- Q93207435 P304 "1683-1689" @default.
- Q93207435 P31 Q13442814 @default.
- Q93207435 P356 "10.1182/BLOODADVANCES.2019001278" @default.
- Q93207435 P433 "8" @default.
- Q93207435 P478 "4" @default.
- Q93207435 P50 Q75025725 @default.
- Q93207435 P50 Q87294607 @default.
- Q93207435 P577 "2020-04-01T00:00:00Z" @default.
- Q93207435 P698 "32330241" @default.
- Q93207435 P932 "7189292" @default.